A considerable number of the patients - pointed out Rodriguez - showed a reduction in the progression of cognitive deterioration and improvement in secondary variables.

Two clinical trials are now planned: one in Havana (comparative) and another one in the rest of the provinces in phase IV. In all cases, the participants will receive drugs for Alzheimer's disease, said Rodriguez, quoted by the Scientific Observatory.

Of the total number of patients in the comparative study, some will be treated with NeuralCIM, while the control group will be given an international standard drug, said the expert.

The specific sites for these trials will be chosen at a meeting with specialists from the Cuban Ministry of Public Health.

In principle, they will include a limited number of patients, but the idea is to increase the number gradually, the specialist commented. Before starting the studies, the team developing the drug will present a protocol for its evaluation by the Center for State Control of Medicines, Equipment and Medical Devices.

Regarding the eligibility criteria, Dr. Rodriguez specified that patients with mild and moderate Alzheimer's disease (symptoms of memory impairment, concentration difficulties, problems in completing daily tasks, confusion about places and passage of time, among others) will be included.

People with Alzheimer-like symptomatology who wish to participate in the study will also be included. They will have to go to the previously announced trial sites to be evaluated by health professionals.

Those who meet the inclusion criteria will be able to participate in the trials, according to the expected number of patients, and when they start the trial they will receive the corresponding treatment.

The expected result will be more information on efficacy and safety, said the project manager.

According to medical literature, Alzheimer's is a progressive mental disease characterized by a degeneration of nerve cells in the brain.

In addition to a decrease in brain mass and the basic manifestations are memory loss, temporal and spatial disorientation and intellectual and personal impairment.